Media

Fusion Pharmaceuticals Presents Imaging Data From Cold Antibody Sub-Study In The Phase 1 Study Of FPI-1434

Fusion Pharmaceuticals And Niowave Announce Actinium-225 Collaboration And Supply Agreement

Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting

Precirix presents preclinical data of its FAP-targeting compound at the SNMMI annual meeting

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients

Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment

Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Precirix strengthens patent portfolio of its precision radiopharmaceuticals platform

Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference